Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Furmonertinib for Residual GGOs in MPLC
NCT04982900Phase 2Unknown
- Sponsor
- Ruijin Hospital
- Start
- Oct 2021
- Primary completion
- Aug 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of furmonertinib in multiple primary lung cancer (MPLC), sponsored by Ruijin Hospital. Status: unknown.
02
Drugs
furmonertinib
03
Conditions
multiple primary lung cancer (MPLC)
Beyond the preview
Go deeper on NCT04982900.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04982900.